Cargando…

Inflammatory bowel disease and risk of Parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals

BACKGROUND: The relationship between inflammatory bowel disease (IBD) and the risk of Parkinson’s Disease (PD) has been investigated in several epidemiological studies. However, the results of these studies were inconclusive and inconsistent. We evaluated the potential relationship between IBD and P...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hong-xing, Zhang, Cui, Zhang, Kai, Liu, Yi-zhe, Peng, Xiao-xiao, Zong, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157095/
https://www.ncbi.nlm.nih.gov/pubmed/37153103
http://dx.doi.org/10.3389/fmed.2023.1137366
_version_ 1785036674194997248
author Li, Hong-xing
Zhang, Cui
Zhang, Kai
Liu, Yi-zhe
Peng, Xiao-xiao
Zong, Qiang
author_facet Li, Hong-xing
Zhang, Cui
Zhang, Kai
Liu, Yi-zhe
Peng, Xiao-xiao
Zong, Qiang
author_sort Li, Hong-xing
collection PubMed
description BACKGROUND: The relationship between inflammatory bowel disease (IBD) and the risk of Parkinson’s Disease (PD) has been investigated in several epidemiological studies. However, the results of these studies were inconclusive and inconsistent. We evaluated the potential relationship between IBD and PD risk by a meta-analysis. METHODS: Search the electronic databases PubMed, Embase and Cochrane databases from inception to November 30, 2022, to identify relevant studies that assess the risk of PD in patients with IBD. The cohort, cross-sectional, mendelian randomization and case-control studies that reported risk estimates of PD and IBD were included in our analysis. The random-effect model and fixed-effects model were used to calculate the summary relative risks (RRs) with 95% confidence intervals (CIs). RESULTS: In total, 14 studies (nine cohort studies, two cross-sectional studies, two mendelian randomization studies and one case-control study) involving more than 13.4 million individuals were analyzed in our analysis. Our results suggested that the risk of PD in IBD patients is moderately increased, with the pooled RR was 1.17 (95% CI: 1.03–1.33, P = 0.019). Omit of any single study from this analysis had little effect on the combined risk estimate. No evidence of publication bias was found. In the subgroup analysis, the combined RR was 1.04 (95% CI: 0.96, 1.12, P = 0.311) for Crohn’s disease (CD), and 1.18 (95% CI: 1.06, 1.31, P = 0.002) for ulcerative colitis (UC). In addition, a significant association was identified in patients with IBD aged ≥ 60 years (RR = 1.22; 95% CI: 1.06–1.41, P = 0.007), but not in age < 60 years (RR = 1.19; 95% CI: 0.58–2.41, P = 0.639). Meanwhile, the meta-analysis results suggested a protective role for IBD medication use against PD development, with the RR was 0.88 (95% CI: 0.74, 1.04, P = 0.126). CONCLUSION: Our results indicated that patients with IBD had a moderately higher risk of PD compared to non-IBD individuals. Patients with IBD should be aware of the potential risks for PD, especially who were ≥ 60 years old.
format Online
Article
Text
id pubmed-10157095
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101570952023-05-05 Inflammatory bowel disease and risk of Parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals Li, Hong-xing Zhang, Cui Zhang, Kai Liu, Yi-zhe Peng, Xiao-xiao Zong, Qiang Front Med (Lausanne) Medicine BACKGROUND: The relationship between inflammatory bowel disease (IBD) and the risk of Parkinson’s Disease (PD) has been investigated in several epidemiological studies. However, the results of these studies were inconclusive and inconsistent. We evaluated the potential relationship between IBD and PD risk by a meta-analysis. METHODS: Search the electronic databases PubMed, Embase and Cochrane databases from inception to November 30, 2022, to identify relevant studies that assess the risk of PD in patients with IBD. The cohort, cross-sectional, mendelian randomization and case-control studies that reported risk estimates of PD and IBD were included in our analysis. The random-effect model and fixed-effects model were used to calculate the summary relative risks (RRs) with 95% confidence intervals (CIs). RESULTS: In total, 14 studies (nine cohort studies, two cross-sectional studies, two mendelian randomization studies and one case-control study) involving more than 13.4 million individuals were analyzed in our analysis. Our results suggested that the risk of PD in IBD patients is moderately increased, with the pooled RR was 1.17 (95% CI: 1.03–1.33, P = 0.019). Omit of any single study from this analysis had little effect on the combined risk estimate. No evidence of publication bias was found. In the subgroup analysis, the combined RR was 1.04 (95% CI: 0.96, 1.12, P = 0.311) for Crohn’s disease (CD), and 1.18 (95% CI: 1.06, 1.31, P = 0.002) for ulcerative colitis (UC). In addition, a significant association was identified in patients with IBD aged ≥ 60 years (RR = 1.22; 95% CI: 1.06–1.41, P = 0.007), but not in age < 60 years (RR = 1.19; 95% CI: 0.58–2.41, P = 0.639). Meanwhile, the meta-analysis results suggested a protective role for IBD medication use against PD development, with the RR was 0.88 (95% CI: 0.74, 1.04, P = 0.126). CONCLUSION: Our results indicated that patients with IBD had a moderately higher risk of PD compared to non-IBD individuals. Patients with IBD should be aware of the potential risks for PD, especially who were ≥ 60 years old. Frontiers Media S.A. 2023-04-20 /pmc/articles/PMC10157095/ /pubmed/37153103 http://dx.doi.org/10.3389/fmed.2023.1137366 Text en Copyright © 2023 Li, Zhang, Zhang, Liu, Peng and Zong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Li, Hong-xing
Zhang, Cui
Zhang, Kai
Liu, Yi-zhe
Peng, Xiao-xiao
Zong, Qiang
Inflammatory bowel disease and risk of Parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals
title Inflammatory bowel disease and risk of Parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals
title_full Inflammatory bowel disease and risk of Parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals
title_fullStr Inflammatory bowel disease and risk of Parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals
title_full_unstemmed Inflammatory bowel disease and risk of Parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals
title_short Inflammatory bowel disease and risk of Parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals
title_sort inflammatory bowel disease and risk of parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157095/
https://www.ncbi.nlm.nih.gov/pubmed/37153103
http://dx.doi.org/10.3389/fmed.2023.1137366
work_keys_str_mv AT lihongxing inflammatoryboweldiseaseandriskofparkinsonsdiseaseevidencefromametaanalysisof14studiesinvolvingmorethan134millionindividuals
AT zhangcui inflammatoryboweldiseaseandriskofparkinsonsdiseaseevidencefromametaanalysisof14studiesinvolvingmorethan134millionindividuals
AT zhangkai inflammatoryboweldiseaseandriskofparkinsonsdiseaseevidencefromametaanalysisof14studiesinvolvingmorethan134millionindividuals
AT liuyizhe inflammatoryboweldiseaseandriskofparkinsonsdiseaseevidencefromametaanalysisof14studiesinvolvingmorethan134millionindividuals
AT pengxiaoxiao inflammatoryboweldiseaseandriskofparkinsonsdiseaseevidencefromametaanalysisof14studiesinvolvingmorethan134millionindividuals
AT zongqiang inflammatoryboweldiseaseandriskofparkinsonsdiseaseevidencefromametaanalysisof14studiesinvolvingmorethan134millionindividuals